FFM
PTGX icon

Fairmount Funds Management’s Protagonist Therapeutics PTGX Stock Holding History

Fairmount Funds Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-931,890
Closed -$32.3M – 16
2024
Q2 		$32.3M Hold
931,890
– – 3.65% 10
2024
Q1 		$27M Buy
+931,890
New +$25.4M 2.94% 11
2022
Q2 		– Sell
-549,988
Closed -$13M – 28
2022
Q1 		$13M Buy
+549,988
New +$15.5M 3.08% 14

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairmount Funds Management's PTGX Position: Q3 2024 in Review

Fairmount Funds Management sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 931,890 shares — an estimated $32.3M sold.

Fairmount Funds Management first reported a position in PTGX in Q1 2022 and held it in 3 quarters. The position peaked at $32.3M in Q2 2024. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Fairmount Funds Management reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fairmount Funds Management sold 931,890 Protagonist Therapeutics shares in Q3 2024, an estimated $32.3M.
  • Fairmount Funds Management first reported a position in Protagonist Therapeutics in Q1 2022 and held it in 3 quarters.
  • Fairmount Funds Management's Protagonist Therapeutics position peaked at $32.3M in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Fairmount Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.